L-selectin controls trafficking of chronic lymphocytic leukemia cells in lymph node high endothelial venules in vivo

Blood

Volumn 126, Issue 11, 2015, Pages 1336-1345

  Lafouresse, Fanny ^a,b   Bellard, Elisabeth ^a,b   Laurent, Camille ^c,d,e   Moussion, Christine ^a,b   Fournié, Jean Jacques ^b,c   Ysebaert, Loïc ^c,e   Girard, Jean Philippe ^a,b  

^a INSTITUT DE PHARMACOLOGIE ET DE BIOLOGIE STRUCTURALE   (France)

^b UNIVERSITÉ PAUL SABATIER   (France)

^c CANCER RESEARCH CENTER OF TOULOUSE   (France)

^d University of Toulouse III   (France)

^e La Croix du Sud Hospital   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIGEN; HOMING RECEPTOR; IDELALISIB; L SELECTIN; ANTINEOPLASTIC AGENT; ENZYME INHIBITOR; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; PURINE DERIVATIVE; QUINAZOLINONE DERIVATIVE;

ARTICLE; BLOOD VESSEL; CANCER PROGNOSIS; CELL ADHESION; CELL MIGRATION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; HIGH ENDOTHELIAL VENULE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; INTRACELLULAR TRANSPORT; LEUKEMIA CELL; LYMPH NODE; LYMPHOID ORGAN; MICROCIRCULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR MICROENVIRONMENT; VENULE; ADULT; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CELL MOTION; INTRAVITAL MICROSCOPY; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPH VESSEL; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY;

ADULT; ANIMALS; ANTINEOPLASTIC AGENTS; CELL ADHESION; CELL MOVEMENT; CLASS IA PHOSPHATIDYLINOSITOL 3-KINASE; ENZYME INHIBITORS; HUMANS; INTRAVITAL MICROSCOPY; L-SELECTIN; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPH NODES; LYMPHATIC VESSELS; MICE; MICE, INBRED C57BL; PURINES; QUINAZOLINONES;

EID: 84942465568     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-02-626291     Document Type: Article

References (37)

1. Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med. 2005;352(8):804-815.
2. Gaidano G, Foà R, Dalla-Favera R. Molecular pathogenesis of chronic lymphocytic leukemia. J Clin Invest. 2012;122(10):3432-3438.
3. Burger JA, Ghia P, Rosenwald A, Caligaris-Cappio F. The microenvironment in mature B-cell malignancies: a target for new treatment strategies. Blood. 2009;114(16):3367-3375.
4. Caligaris-Cappio F, Bertilaccio MT, Scielzo C. How the microenvironment wires the natural history of chronic lymphocytic leukemia. Semin Cancer Biol. 2014;24:43-48.
5. Burger JA, Montserrat E. Coming full circle: 70 years of chronic lymphocytic leukemia cell redistribution, from glucocorticoids to inhibitors of B-cell receptor signaling. Blood. 2013;121(9):1501-1509.
6. Hayden RE, Pratt G, Roberts C, Drayson MT, Bunce CM. Treatment of chronic lymphocytic leukemia requires targeting of the protective lymph node environment with novel therapeutic approaches. Leuk Lymphoma. 2012;53(4):537-549.
7. Burger JA. Chemokines and chemokine receptors in chronic lymphocytic leukemia (CLL): from understanding the basics towards therapeutic targeting. Semin Cancer Biol. 2010;20(6):424-430.
8. Burger JA, Burger M, Kipps TJ. Chronic lymphocytic leukemia B cells express functional CXCR4 chemokine receptors that mediate spontaneous migration beneath bone marrow stromal cells. Blood. 1999;94(11):3658-3667.
9. Till KJ, Lin K, Zuzel M, Cawley JC. The chemokine receptor CCR7 and alpha4 integrin are important for migration of chronic lymphocytic leukemia cells into lymph nodes. Blood. 2002;99(8):2977-2984.
10. López-Giral S, Quintana NE, Cabrerizo M, et al. Chemokine receptors that mediate B cell homing to secondary lymphoid tissues are highly expressed in B cell chronic lymphocytic leukemia and non-Hodgkin lymphomas with widespread nodular dissemination. J Leukocyte Biol. 2004;76(2):462-471.
11. Trentin L, Cabrelle A, Facco M, et al. Homeostatic chemokines drive migration of malignant B cells in patients with non-Hodgkin lymphomas. Blood. 2004;104(2):502-508.
12. Bürkle A, Niedermeier M, Schmitt-Gräff A, Wierda WG, Keating MJ, Burger JA. Overexpression of the CXCR5 chemokine receptor, and its ligand, CXCL13 in B-cell chronic lymphocytic leukemia. Blood. 2007;110(9):3316-3325.
13. Girard JP, Moussion C, Förster R. HEVs, lymphatics and homeostatic immune cell trafficking in lymph nodes. Nat Rev Immunol. 2012;12(11):762-773.
14. Moussion C, Girard JP. Dendritic cells control lymphocyte entry to lymph nodes through high endothelial venules. Nature. 2011;479(7374):542-546.
15. von Andrian UH. Intravital microscopy of the peripheral lymph node microcirculation in mice. Microcirculation. 1996;3(3):287-300.
16. Rosen SD. Ligands for L-selectin: homing, inflammation, and beyond. Annu Rev Immunol. 2004;22:129-156.
17. Gallatin WM, Weissman IL, Butcher EC. A cell-surface molecule involved in organ-specific homing of lymphocytes. Nature. 1983;304(5921):30-34.
18. Arbonés ML, Ord DC, Ley K, et al. Lymphocyte homing and leukocyte rolling and migration are impaired in L-selectin-deficient mice. Immunity. 1994;1(4):247-260.
19. Furman RR, Sharman JP, Coutre SE, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014;370(11):997-1007.
20. Hoellenriegel J, Meadows SA, Sivina M, et al. The phosphoinositide 3′-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood. 2011;118(13):3603-3612.
21. Mitsuoka C, Sawada-Kasugai M, Ando-Furui K, et al. Identification of a major carbohydrate capping group of the L-selectin ligand on high endothelial venules in human lymph nodes as 6-sulfo sialyl Lewis X. J Biol Chem. 1998;273(18):11225-11233.
22. Faveeuw C, Preece G, Ager A. Transendothelial migration of lymphocytes across high endothelial venules into lymph nodes is affected by metalloproteinases. Blood. 2001;98(3):688-695.
23. Mionnet C, Sanos SL, Mondor I, et al. High endothelial venules as traffic control points maintaining lymphocyte population homeostasis in lymph nodes. Blood. 2011;118(23):6115-6122.
24. Onder L, Danuser R, Scandella E, et al. Endothelial cell-specific lymphotoxin-β receptor signaling is critical for lymph node and high endothelial venule formation. J Exp Med. 2013;210(3):465-473.
25. Kamel-Reid S, Letarte M, Sirard C, et al. A model of human acute lymphoblastic leukemia in immune-deficient SCID mice. Science. 1989;246(4937):1597-1600.
26. Park C, Hwang IY, Sinha RK, Kamenyeva O, Davis MD, Kehrl JH. Lymph node B lymphocyte trafficking is constrained by anatomy and highly dependent upon chemoattractant desensitization. Blood. 2012;119(4):978-989.
27. Uchimura K, Gauguet JM, Singer MS, et al. A major class of L-selectin ligands is eliminated in mice deficient in two sulfotransferases expressed in high endothelial venules. Nat Immunol. 2005;6(11):1105-1113.
28. Warnock RA, Askari S, Butcher EC, von Andrian UH. Molecular mechanisms of lymphocyte homing to peripheral lymph nodes. J Exp Med. 1998;187(2):205-216.
29. Spertini O, Freedman AS, Belvin MP, Penta AC, Griffin JD, Tedder TF. Regulation of leukocyte adhesion molecule-1 (TQ1, Leu-8) expression and shedding by normal and malignant cells. Leukemia. 1991;5(4):300-308.
30. Drillenburg P, Pals ST. Cell adhesion receptors in lymphoma dissemination. Blood. 2000;95(6):1900-1910.
31. Brown JR, Byrd JC, Coutre SE, et al. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia. Blood. 2014;123(22):3390-3397.
32. Gauguet JM, Rosen SD, Marth JD, von Andrian UH. Core 2 branching beta1,6-N-acetylglucosaminyltransferase and high endothelial cell N-acetylglucosamine-6-sulfotransferase exert differential control over B- and T-lymphocyte homing to peripheral lymph nodes. Blood. 2004;104(13):4104-4112.
33. Simonetti G, Bertilaccio MT, Ghia P, Klein U. Mouse models in the study of chronic lymphocytic leukemia pathogenesis and therapy. Blood. 2014;124(7):1010-1019.
34. Lacorre DA, Baekkevold ES, Garrido I, et al. Plasticity of endothelial cells: rapid dedifferentiation of freshly isolated high endothelial venule endothelial cells outside the lymphoid tissue microenvironment. Blood. 2004;103(11):4164-4172.
35. Capitani N, Patrussi L, Trentin L, et al. S1P1 expression is controlled by the pro-oxidant activity of p66Shc and is impaired in B-CLL patients with unfavorable prognosis. Blood. 2012;120(22):4391-4399.
36. Till KJ, Pettitt AR, Slupsky JR. Expression of functional sphingosine-1 phosphate receptor-1 is reduced by B cell receptor signaling and increased by inhibition of PI3 kinase δ but not SYK or BTK in chronic lymphocytic leukemia cells. J Immunol. 2015;194(5):2439-2446.
37. Fiorcari S, Brown WS, McIntyre BW, et al. The PI3-kinase delta inhibitor idelalisib (GS-1101) targets integrin-mediated adhesion of chronic lymphocytic leukemia (CLL) cell to endothelial and marrow stromal cells. PLoS One. 2013;8(12):e83830.